Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Entheon Biomedical Corp ENTBF


Primary Symbol: C.ENBI

Entheon Biomedical Corp. is a Canada-based biotechnology research and development company. The Company is focused on treating addiction and substance-use disorders.

Recent & Breaking News (CSE:ENBI)

Entheon Biomedical (CSE:ENBI) appoints Dr. David Erritzoe to Advisory Board

Trevor Abes  August 25, 2021

Clinical Director of Imperial College's Center for Psychedelic Research Joins Entheon Advisory Board

Newsfile August 25, 2021

Entheon Biomedical Corp. Announces DTC Eligibility

Newsfile August 24, 2021

CORRECTION FROM SOURCE: BTV Examines the Rapidly Expanding Psychedelics Market

Newsfile August 17, 2021

BTV Examines the Rapidly Expanding Psychedelics Market

Newsfile August 17, 2021

Entheon Biomedical (CSE:ENBI) sponsors ketamine study by Heading Health

Julia Kennedy  August 12, 2021

Entheon Biomedical Announces Sponsorship of a Clinical Study to Assess the Electroneurophysiologic Effects of Ketamine

Newsfile August 12, 2021

Entheon Biomedical Corp. (CSE:ENBI) acquires Lobo Genetics Inc.

Brieanna McCutcheon  July 30, 2021

Entheon Biomedical Corp. Acquires Lobo Genetics Inc.

Newsfile July 30, 2021

Entheon Biomedical (CSE:ENBI) welcomes Dr. Andy Greenshaw

John Ballem  July 28, 2021

Entheon Biomedical Further Strengthens Advisory Board with Appointment of Dr. Andy Greenshaw

Newsfile July 28, 2021

Microdose Is Pleased to Announce the DMT Conference: A Molecular Masterclass

Newsfile July 27, 2021

Entheon Biomedical Announces Medical Advisor, Dr. Dinesh Bhayana

Newsfile June 30, 2021

HaluGen Life Sciences partners with Maya Health to drive psychedelics genetic test kit awareness

Julia Kennedy  June 25, 2021

Entheon Subsidiary, HaluGen Life Sciences, Partners with Maya Health to Drive Psychedelics Genetic Test Kit Awareness

Newsfile June 25, 2021

Entheon Biomedical (CSE:ENBI) subsidiary partners with 3W Wellness

Trevor Abes  June 22, 2021

Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Third Wave

Newsfile June 22, 2021

Entheon Biomedical's Wholly-Owned Subsidiary, HaluGen Life Sciences and Silo Wellness Announces Psychedelics Genetic Test Kit Partnership

Newsfile June 17, 2021

Entheon Biomedical (CSE:ENBI) acquires Lobo Genetics

Julia Kennedy  June 16, 2021

Entheon Biomedical Corp. Announces Agreement to Acquire Lobo Genetics Inc.

Newsfile June 16, 2021